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Adeno-associated virus (AAV) has emerged as a leading gene-therapy candidate due to its 
broad tissue tropism and encouraging safety profile. Traditionally, viral biodistribution is 
assessed through expression of reporter genes in tissues days to weeks post-vector 
administration. This does not provide insight into how AAV initially distributes throughout 
the body which will impact its effectiveness and long-term safety. Towards this end, we 
optimized a strategy for assembling a viral like particle (VLP) using capsid proteins from 
AAV serotype 2 and incorporated a quantum dot (QD) into its core. Their uptake was 
visualized in human embryonic kidney (HEK) cells in vitro. Our findings enable further 
optimization of VLP-QD systems for AAV biodistribution analysis. In addition, 
extracellular vesicles (EVs) are a new class of gene-delivery vector with potential in 
pulmonary disease. We measured the diffusion of EVs from two cell lines in human mucus 
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Significance and Motivation 
AAV is a leading in vivo gene therapy candidate due to its mild immune response, its ability 
to transduce a variety of cell types and its stably expressed episomal gene product. 
Understanding its biodistribution soon after administration could provide useful 
knowledge to enhance its already appealing traits. Quantum dots (QDs) have been used in 
many different in vivo imaging applications, including for biodistribution and to obtain 
high intensity fluorescence images with low amounts of background1. By incorporating 
QDs directly into the capsid of a virus, it will be possible to obtain better insight into the 
cellular uptake process in vitro and the real-time biodistribution of the virus in vivo. Similar 
work has been done using Brome mosaic virus, a similar non-enveloped, icosahedral virus, 
which indicates it may be also possible with the AAV capsid2. There has been some success 
incorporating QDs into the viral capsid, however, the only study to do so with AAV used 
well-established EDC-NHS chemistry to attach it onto the outside of the capsid3. While 
this can still be effective for following the AAV uncoating process in vitro, a 25% increase 
in diameter could significantly alter how the particles move in a complex, 3D biological 
system.  
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Chapter One: Background 
Viral-Based Gene Therapy: Adeno-Associated Virus 
Gene Therapy 
Gene therapy has become a promising technology to supplement or correct a defective gene 
in place of treating symptoms throughout a patient’s life. There are many ways to deliver 
a gene into a host nucleus, such as using a non-viral vector to deliver CRISPR-cas9, 
transcription activator-like effector nucleases (TALENs) or zinc-finger nucleases (ZFNs), 
which can be effective however they suffer from low efficiency4,5. Viral vectors, on the 
other hand, have an innate ability to hijack cellular machinery to generate complex proteins 
using their genome as a template and they require no extra technology to aid in gene 
transfer. Viruses have gained traction due to their natural ability to infect a variety of cell 
types and their engineered potential to evade the complex human immune system. 
Worldwide, there are 3704 ongoing clinical trials using gene therapy, with viruses 
dominating the majority of recent successes. Of the viral based gene therapies 34% use a 
retrovirus (RV), 32% use Adenovirus (AdV), 10% use Herpes Simplex Virus (HSV) and 
24% use Adeno-Associated Virus (AAV)6. In 2017, the first AAV-based gene therapy, 
Luxterna, was FDA approved to treat patients with RPE65-associated Leber Congenital 
Amaurosis, an inherited disorder that causes blindness. The FDA has since released a report 
reducing the stringency of approval for viral-based gene therapies, which will significantly 
increase the number of emerging viral-based drugs7. Of the viruses capable of delivering a 
corrective gene, most have been retroviral (RV), meaning they carry a single stranded RNA 
genome and must be transcribed into DNA via reverse transcriptase before insertion to the 
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host genome. Most RV drugs must be used ex-vivo due to the difficulty of restricting 
insertion events in vivo, which can result in side effects such as cancer6. Although they 
have become limited to ex vivo usage, they are actually far superior for those purposes 
because they integrate into the host genome allowing for long term expression in dividing 
cells8. AAV, on the other hand, is more suitable for in vivo usage because of their mild 
safety profile and their ability to stably express episomal DNA in non-dividing cells9.  
Adeno-Associated Virus 
AAV was originally discovered in a preparation of Simian AdV that was initially thought 
to be contaminated10. It was soon realized that AAV was its own virus and was simply 
replication defective. In regard to gene therapy, it has become a particularly good 
alternative to other viruses because of its low pathogenicity. It also has a variety of naturally 
occurring serotypes and it rarely, but predictably, inserts into the host’s genome at AAV 
integration site 1 (AAVS1) on Chromosome 19. It is a non-enveloped parvovirus with a 
capsid 22nm in diameter. The genome is a single strand of DNA (ssDNA), 5kb in length 
with one inverted terminal repeat (ITR) on each end. The genome is made up of two genes, 
rep and cap. Rep encodes for Rep78, Rep68, Rep52 and Rep40 (named from their 
approximate molecular weights) from a single open reading frame (ORF). The two larger 
rep proteins, Rep78 and Rep68, are necessary for replication and have endonuclease and 
ATP-dependent helicase function11. The smaller two rep proteins, Rep52 and Rep40, act 
as motor proteins that package the newly synthesized genome into mature AAV 
capsids12,13. The three capsid proteins (CP) are translated from the cap gene and are 
designated VP1, VP2 and VP3. They are regulated by the combination of a rare start codon 
(ACG) and alternative splicing, causing the VP1 and VP2 proteins to have the same amino 
 3 
 
acid sequence as VP3 at their C-terminus. The mature AAV capsid is comprised of 60 CPs 
in a 1:1:10 ratio (VP1:VP2:VP3) held together in icosahedral geometry. The subunits form 
2-fold, 3-fold and 5-fold axes of symmetry with a depression located along the 2-fold axis, 
3 protrusions surrounding a depression on the 3-fold axis and a small channel located at 
the center of the 5-fold axis (Figure 1.1)14. AAV can be fully formed and packaged by 







Figure 1.1: Capsid surface symmetry of AAV216. A) Shows the 2-fold axis of 
symmetry B) shows the 3-fold axis of symmetry and C) shows the 5-fold axis of 
symmetry. 
Cell Entry 
Currently there are 12 known naturally occurring serotypes of AAV, each using a different 
combination of primary and co-receptors. Most serotypes use sialic acid, heparin sulfate or 
galactose as their primary receptors and are subsequently endocytosed. They can enter 
using clathrin-independent carriers and GPI-anchored-protein-enriched endosomal 





late-endosome is carried closer to the nucleus, the acidification process alters the 
conformation of CPs VP1 and VP2, which exposes their N-terminus. The N-terminus of 
VP1 has been shown to have phospholipase activity and is required for successful infection 
of AAV19. The intact AAV virions then can escape from the late-endosome and accumulate 
in the peri-nuclear region of the cell. The virions then translocate into the nucleus, the 
genome is released, and second strand synthesis can begin. The ssDNA is first converted 
into a double-stranded template, a process initiated by the ITRs, which allows the genome 
to be transcribed or inserted into AAVS120. Of the entire AAV genome, the only regions 
necessary for efficient transgene expression are the ITRs21. Since they only make up 4% 
of the genome, the remaining 96% can be replaced with a therapeutic transgene, which 
must include a promotor and a poly-A tail. 
Transgene 
The design of a therapeutic gene cassette is essential for optimizing protein expression and 
function. Many studies have been done to optimize the ITR sequence due to their essential 
roles in cell transduction and propagation. Until the genome is double stranded it cannot 
undergo transcription, thus, prohibiting translation and subsequent protein production. This 
rate-limiting step can be bypassed by introducing a mutation into one of the ITRs by 
removing the binding motif of Rep78 and Rep68, which prevents them from induce second 
strand synthesis. Instead, the wild-type and mutated ITR form a circular, self-
complementary genome that is capable of priming its own second strand22. The main 
drawback of self-complementary AAV’s (sc-AAV) is that they must include the plus and 
minus strands of DNA making this method impractical for transgenes larger than 2.5kb. 
Splitting the transgene into two or many distinct recombinant AAV (rAAV) allows for 
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expression for a larger transgene than by using a single rAAV. It takes advantage of 
homologous recombination (HR) that occurs from the presence of overlapping ITRs23,24. 
Recombination specific sequences can also be added to the ends of random transgene 
fragments to induce recombination at more specific locations. This optimizes the 
recombination events to promote the formation of a final product that is a completely intact 
transgene larger than 5kb25.  
Immune Response 
The human body can mitigate AAV infection by preventing cell-entry through capsid 
recognition, recognizing the viral DNA inside the cell or recognizing the products of 
transcription/translation of the viral transgene26. The two main roadblocks to successful 
transduction of AAV are neutralizing antibodies (NAbs) and cytotoxic T lymphocytes 
(CTLs). NAbs help prevent the initial binding of AAV to its primary receptor by 
recognizing and binding to specific motifs on the AAV capsid. This has proven to be very 
difficult to overcome because as much as 50% of the population already has NAbs for 
many of the wild-type AAVs (wt-AAV)27. Another cellular response to AAV infection 
when the capsid has any exposed tyrosine residues on its capsid. The tyrosine is 
phosphorylated, and ubiquitinated, followed by degradation by the proteasome28. After 
degradation, the individual AAV CPs are processed through the transporter associated with 
antigen processing (TAP), which allows these capsid fragments to be bound by major 
histocompatibility complex (MHC) class I molecules and subsequently transported to the 
cell surface29,30. When MHC class I molecules are present on the cell surface, CTLs 
recognize this signal and destroy the infected cell.  
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The last possible immune response to AAV is when the cell identifies the therapeutic 
transgene expression as foreign. This can happen when the host’s disease is one caused by 
a deletion mutation, where the introduction of the newly synthesized peptide sequence is 
considered “unknown” and is targeted by CD8+ T cells, thus, undoing the successful 
delivery of a therapeutic protein31. Because these immune responses rely on recognizing a 
specific motif on the viral capsid or the binding of specific, well-characterized molecules, 
many of these responses can be evaded by the utilization of an engineered capsid or can be 
reduced by the addition of other small molecules that interfere with the cellular response 
pathways.   
An easy pathway to target to interfere with is the proteasome-based degradation pathway. 
By using an already FDA approved proteasome inhibitor, the ubiquitylation of the capsid 
can be blocked, which allows a higher concentration of AAV to be trafficked into the 
nucleus rather than degraded32. Many other approved small molecules have been identified 
through high-throughput screening methods; many of which are topoisomerase inhibitors 
that induce host DNA damage33. The increased DNA damage may “distract” the cellular 
machinery away from the viral DNA long enough to allow the majority of ssDNA to 
become dsDNA. Inhibition of many DNA damage pathways has been linked to AAV 
transduction enhancement, however the exact mechanism remains unknown34,35. 
Capsid Engineering 
Many different methods have proven successful in evading neutralizing antibodies. Cell 
targeting peptides have become an easy way to change the primary receptor AAV uses to 
enter the cell. This can be done by replacing residues on VP1, forcing different amino acids 
to be exposed on the surface36,37. By doing this, the rAAV capsid is undetectable to NAbs 
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because the motif they recognize would no longer be present. The main drawback of this 
method is that it can significantly alter receptor binding affinity. However, by using this 
method in conjunction with an uptake assay, the AAV capsid modifications that are 
successfully transduced can be isolated and obtained.  
Using random peptide libraries, instead, relies on the introduction of random mutations 
rather than the change in selected residues. After the generation of an rAAV library with 
many random mutations, random peptide rAAVs are added to cells in vitro. The rAAV that 
are successfully transduced are characterized and subsequently cataloged to then be used 
for transgene delivery38. The third approach uses the cap gene from multiple serotypes 
produce a variation of CPs. When capsid assembly begins in vitro, proteins from all added 
serotypes come together to form a polyploid capsid39. Instead of having many binding sites 
per particle for NAbs to recognize and a single primary receptor, particles can enter cells 
via multiple primary receptors and better evade the NAbs already present39. 
The last method, directed evolution, can be done using three different approaches: in silico, 
in vitro or in vivo. In silico uses computational modeling to identify protein fragments that 
have no effect on the 3D structure of the capsid in order to ensure proper folding and 
functionality40. The in vitro approach utilizes a genome shuffling technique, usually error-
prone PCR or a random genome insertion, to introduce random mutations into the AAV 
capsid with subsequent rounds of transduction, harvesting and amplification. It is also 
possible to include an incubation step with NAbs to select against a potential immune 
response. After many rounds, the rAAV capsid will be altered to minimize NAb 
recognition and maximize transduction of the chosen cell type41. The in vivo approach uses 
the same concept as in vitro, however the process selects against the host’s immune 
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response as well. After the target tissue is harvested, the AAV sequence can be amplified 
and purified42. This method has been successfully used to administer a truncated form of 
the cystic fibrosis transmembrane regulator (CFTR) to a porcine knock-out model after 
multiple rounds of selection43. 
In vitro Production 
To successfully generate mature rAAV capsids in vitro, a cell line requires co-infection 
with another virus, typically AdV or HSV. The cultured cells are typically ones that grow 
very quickly such as HeLa or HEK293. The process includes transfecting the cells with 3 
plasmids that contain a therapeutic gene of choice flanked by the 2 ITRs, the rep and cap 
genes, and the helper-virus genes that induce viral replication. Once mature rAAV are 
produced, the culture medium is collected, and the rAAV are subsequently purified. This 
process consists of sucrose, CsCl or Iodixanol gradients, and various types of 
chromatography (affinity, ion exchange, size exclusion, etc.). Depending on the chemistry 
of the capsid, one method may be more advantageous than another. By using 3 sperate 
plasmids rather than a single plasmid, each can easily be modified separately and 
systematically to engineer novel AAV strains and to manipulate the AAV genome to 
elucidate the unknown biological processes of AAV. 
Adeno-Associated Virus Assembly 
AAV assembly is believed to take place in the nucleolus, however the exact mechanism 
has yet to be elucidated44. By using a Pulse-Chase technique, Myers and Carter showed 
that AAV2 makes empty capsids very quickly and that the rate-limiting step of forming a 
fully functional AAV2 particle lies with the rate of genome insertion45. Once the intact 
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capsid leaves the nucleolus, its replicated genome can then be inserted through the 
combination of the large rep proteins interacting with the capsid and the smaller rep 
proteins acting as a motor to insert the ssDNA through one of the pores located at a 5-fold 
axes of symmetry46.   
In 2010, a ‘+1' frameshifted ORF was identified in the Cap gene of AAV2 that coded for a 
204 amino acid protein called Assembly Activating Protein (AAP)47. An AAP has been 
found in all other AAV serotypes and contains many conserved residues; it is deemed 
essential for nearly all serotypes48. To determine AAPs role in assembly, Naurer et al. 2012 
introduced an early stop codon into the reading frame of AAP from AAV2 (AAP2) such 
that it had no effect on potential downstream alternate start codons and was upstream of 
essential amino acids49,50. The stability of the capsid proteins was assessed in vitro by 
inhibiting the proteasomal degradation pathway with and without AAP. Without AAP, CPs 
were degraded by proteasomal degradation, however after adding AAP back in trans, AAV 
capsid assembly was almost completely rescued to its wild-type titer50.  
Until recently, all assembly related work with AAP-CP interactions had been done with 
VP3-only capsids. When similar AAP2 knock-out experiments were performed using all 
AAV CPs, it was determined that AAP2 was indeed essential for AAV2 CP stability and 
assembly in vitro, however each serotype has its own AAP with slightly different nuclear 
localization signals51. It was later determined that some serotypes have nucleolar or nuclear 
localization signals, while others were found in both locations52. This study hinted at the 
fact that AAPs function has more to do with protein stability than nuclear transportation 




Investigating Transgene Delivery 
Currently the most commonly utilized methods to test for rAAV transduction in vitro are 
by fluorescence detection after reporter transgene expression or by using a qPCR-based 
assay. In vitro, these methods are easily performed by putting infected cells under a 
fluorescent microscope or by assessing mRNA levels after a simple lysing step. While 
these methods may also be used in vivo, they are considerably more difficult. In many 
cases, the animal must be sacrificed to isolate the target tissue prior to fluorescent detection. 
There has been some success in a non-invasive viral detection method using firefly 
luciferase. After viral transduction, the IVIS system (Perkin Elmer) can be used to assess 
bioluminescence after luciferin injection53. As powerful as this method is, the fluorescence 
can only be detected after the luciferase enzyme is expressed and cannot give any indication 
of the real-time biodistribution of the virus. 
Viral-Like-Particle Assembly 
Viral Assembly 
Viruses such as Tobacco Mosaic Virus (TMV) or Brome Mosaic Virus (BMV) have basic 
capsids consisting of multiple copies of the same subunit. Because they have “simple” 
capsids, it is possible to take the disassembled individual capsid building blocks and 
assemble functional viral like particles (VLPs) with capsids and transduction comparable 
to the wild type54,55. This can be achieved in a test tube either by increasing the number of 
capsid subunits above a critical concentration or by dialyzing against a buffer with 
favorable assembly conditions56,57. Unlike pathogenic viruses, there has been little 
scientific demand to research AAV’s assembly mechanism. However, due to its recent 
 11 
 
success in clinical trials, a better understanding of its intracellular assembly processes has 
become necessary to help minimize self-inhibitory effects from genetic alterations 
introduced from capsid engineering. 
Methods of Viral Assembly Around Quantum Dots 
Because of their appealing optical properties, QDs have started to be utilized in a variety 
of bioimaging techniques. Of the many methods of QD attachment, one of great appeal is 
the internal labeling of viral capsids. There have been a number of published studies done 
to generate VLP-QD hybrid particles; each has used a slightly different approach. The most 
common of these approaches was done by first disassembling the capsid, then removing 
the nuclei acids. This step is followed by a second round of dialysis with a lower ionic 
strength buffer causing the protein dimers to reassemble. Although dialysis has been used 
to reassemble many different viruses, incorporation of a quantum dot has only been done 
in a few, the first being BMV. Dixit et. Al showed that during the reassembly step, QDs 
can be combined with the individual proteins in order to be encapsulated by the newly 
formed VLPs2. A similar method was also done with canine parvovirus, another non-
enveloped, icosahedral virus. The only difference with their method was that they made 
the viral proteins in E. coli rather than disassembling the intact canine parvovirus to obtain 
them58. 
The second of these methods relies on changes in concentration to initiate VLP formation 
rather than manipulation of buffer conditions. This work was performed using the MS2 
bacteriophage, whose capsid disassembles into basic dimers. Various concentrations of 
dimers were filtered through a 100 kDa membrane to identify the concentration at which 
yielded the majority of capsids rather than dimers59. By simply combining QDs with a 
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concentration of MS2 dimers above their critical concentration, it was possible to 
encapsulate QDs into the core of the resulting VLPs60. 
Therapeutic Nanocarriers: Extracellular Vesicles 
Extracellular Vesicles  
Extracellular vesicles (EV) are a heterogeneous population of lipid membrane vesicles 
released from most cells and play a huge role in cell-cell communication61. They can be 
categorized into three different subgroups based on their origin (Figure 1.2). Apoptotic 
bodies are the result of controlled cell death and are between 1µm and 5µm. The second 
largest are microvesicles and are formed by the outward budding of the plasma membrane 
to form vesicles 100nm-1µm in diameter. The smallest of the vesicles are exosomes, which 
are between 30nm and 150nm. They were first discovered in 1983 budding off of maturing 
reticulocytes, however, they have been found in many different types of bodily fluids since 
then6263. Exosomes originate in the late endosome as it begins its inward budding process, 
leading to the formation of multivesicular bodies (MVB). Cytosolic macromolecules and 
proteins are internalized by the newly forming vesicles. As the MVB fuse with the cell 
membrane, its vesicular contents are released outside of the cell as exosomes64. 
EVs, in particular, have become a vehicle of interest due to their natural ability to hold 
cargo such as proteins, lipids, mRNA and non-coding RNA depending on their donor cell-
type. They have also had success in targeting tumors, due to the abundant expression of 










Figure 1.2: Schematic of EV formation. Depiction of the formation of an 
apoptotic body (I), mivrovesicles (II), multivesicular bodies (III) and exosomes 
(IV).  
Extracellular Vesicle Production and Purification 
EVs are typically isolated from conditioned media that is first collected and then processed 
through a series of centrifugation steps to remove large particulates. Following the first 
step, many aggregates and larger vesicles still remain, requiring the use of a density 
gradient. Although this method can be effective, a filtration step is commonly used at the 
end to maximize purity. Because of the overlapping size and density ranges of the different 
types of vesicles, most procedures end up isolating a heterogenous population of EV.  
EVs commonly carry specific proteins such as cluster of differentiation (CD) molecules 
which can be used to help characterize the newly isolated population66. These molecules 
are used in immunophenotyping and play important roles in cell signaling and cell 
adhesion. By using these molecules, EVs can be targeted by antibodies conjugated to a 
resin or a magnetic bead as an alternative method of purification; however, it is important 
to recognize that other cellular particles could also contain the target CD protein67.    
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Extracellular Vesicles as Nanocarriers  
The hydrophilic core of EVs makes it possible to engineer them to carry biologically active 
molecules (Figure 1.3). The majority of the EV’s cargo comes from its donor cell, 
therefore it is vital to use a cell type that will not interfere with the intended result; the 
donor cell type can have drastic effects on the fate of the EV. For example, mouse tumor 
derived EVs (Td-EV) isolated in vitro and then transferred on to human dendritic cells have 
been shown to gain a potent tumor antigen response68. However, other studies have shown 
that Td-EVs also play a role in tumor metastasis69. These polar-opposite responses illustrate 
the importance of the cargo, depending on the tumor cell of origin and the possible 
downstream effects on metastasis and the immune system. Although the response of Td-
EVs is difficult to predict, further characterization has given them an emerging role as a 
tumor diagnostic70. The monitoring of micro-RNA (miRNA) levels, in particular, has 
become powerful in recognizing various diseases due to the ease of PCR-based methods 
and how readily accessible EVs are in many parts of the body71. Not only do they have 
potential in diagnostics and tumor targeting, in 2007 EVs were observed to deliver mRNA 














Figure 1.3: Schematic of the potential cargo of an EV   
Therapeutic Loading of Extracellular Vesicles 
They have appealing qualities as a nanocarrier; however, they are only as effective as their 
drug loading efficiency. Each method has its benefits and drawbacks; however, some are 
still preferred over others. Simple diffusion relies on a drugs ability to diffuse through the 
membrane to satisfy the concentration gradient. This slow and imprecise method is only 
possible for drugs that can penetrate its lipid bilayer. Because EVs are typically harvested 
from a donor cell line, it is also possible to add the drug directly to the culture medium 
allowing it to be taken up by the cells; thereby, the EVs produced already contain the drug. 
Although these methods are easy to perform, it is not possible to load cargo such as small-
interfering RNA (siRNA) or miRNA, which are too large to diffuse through the membrane. 
These small, non-coding RNA molecules are important in many biological processes, most 
importantly, they interact with the RNA-induced silencing complex73. This complex seeks 
out its target mRNA and silences translation via endonuclease activity74.  
The active loading techniques are very effective but also much more disruptive to the 
membrane. Sonication is an appealing method because of its efficiency and practicality; 
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however, the drug can attach onto the membrane as well as inside the vesicle, giving the 
EV an unintended dual-phase drug release. Extrusion is by far the most disruptive method 
for the membrane and consists of pushing the drug and EV mixture through a porous 
membrane (100nm-400nm) with a syringe. Electroporation is another method capable of 
loading siRNA and miRNA. Electroporation uses an electric field to disturb the integrity 
of the membrane causing small pores to appear. The opening of these pores allows for the 
drug to flow into the core of the EV in a way that minimizes membrane disruption. 
Although this method is widely used, it can lead to RNA or EV aggregation. By optimizing 
the electroporation buffer, these effects can be minimized75. A new, appealing way to load 
EVs is by using a pH gradient. By using a pH gradient, non-coding RNA molecules were 
loaded successfully into purified EVs at comparable concentrations to electroporation and 
sonication without the use of any external energy to disrupt the membrane76. EVs have the 
potential to efficiently penetrate through the mucus barrier, as they play in important cell-








Chapter Two: Quantum Dots Encapsulated by Viral like Particles Based 
on Adeno-Associated Virus 
Introduction 
The field of gene therapy has been rapidly growing given its possibility to treat an 
abundance of diseases77. AAV, especially, has emerged as a leading gene delivery vector 
because of its naturally occurring serotypes with the ability to target a variety of tissues 
and its minimal immune response. Given the variety of tissues the naturally occurring AAV 
serotypes can target, it is important to understand what happens to them directly after 
administration, and before they reach their intended target. Traditionally, the location of 
AAVs, once administered in vivo, only becomes known upon expression of a fluorescent 
reporter gene78–80. Waiting for a reporter to be expressed can take days to weeks, which 
makes fluorescent labeling an appealing approach. However, if this type of approach were 
attempted in vivo using a dye, the fluorescence intensity would be far too low for real-time 
measurements. Fluorescent labeling generally only works in vitro however, a capsid fully 
saturated with dye or nanoparticles dragging behind may significantly affect their natural 
surface and how they react in a biological environment. 
The convenient optical properties of CdSe quantum dots (QDs) provide the ability to 
achieve single particle resolution in vitro and increased resolution in vivo due to their 
inherent brightness and long-lasting photostability81,82. These benefits make it 
advantageous to incorporate them into bio-imaging techniques, and more importantly, into 
the imaging of gene-delivery vehicles, to better assess particle location in real-time.  
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Previous studies have incorporated QDs into viral capsids to form viral like particles (VLP-
QDs), however this has yet to be done with AAV83–87. Although a QD has successfully 
been attached to the outside of an AAV capsid for cellular uptake observation, a 25% 
increase in particle size at the nanoscale can significantly alter how it behaves in solution, 
not to mention a biological landscape3. Another study encapsulated Brome Mosaic Virus 
(BMV), a 25nm icosahedral, non-enveloped virus, with a QD by first disassembling the 
capsid and reassembling the capsid proteins around the QDs in suspension 85. The newly 
assembled virus or VLP, closely resembles the wild-type virus (wt-virus) containing the 
same capsid proteins. Although VLPs can differ structurally from the wt-virus, they can 
still provide valuable insight into its behavior.  
We sought to incorporate a single QD into a VLP made of AAV2 capsid proteins to gain 
the ability to assess biodistribution in real-time. This work has the potential to provide 
insight into AAV circulation time and real-time distribution of AAV in tissues. This 
protocol initially used for BMV, was adapted for AAV to insert a single QD into its core 
to provide the optical benefits of a QD while maintaining the surface integrity of the AAV2 
capsid.  
Materials and Methods 
Assembly of AAV2 VLP-QD’s  
The AAV2 CMV-Null virions were acquired from Vector Biolabs (Cat 7026). The intact 
AAV2 virions (2.5x1012 vg/mL) were first disassembled by performing dialysis against 
500mM CaCl2 solution at 4 °C for 24h. All dialysis steps were performed using slide-a-
lyzer mini dialysis devices (10kDa MWCO) against 200mL buffer. The ssDNA was 
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removed by centrifugation at 16,000 x g for 20 min at 4 °C. The supernatant containing the 
disassembled capsid subunits was dialyzed against 10mM Tris, pH 7.4 for 24h at 4 °C to 
remove residual calcium ions. The surface of the QDs used in all experiments were 
functionalized with carboxyl groups. QDs with emission maximums at 605nm and 525nm 
were used (Thermo Fisher). To encapsulate the QDs with the capsid subunits, a 2:1 ratio 
of QDs to AAV was combined and dialyzed against reassembly buffer (50mM Tris + 
50mM NaCl + 1mM KCl + 5mM MgCl2, pH 7.4) at 4 °C for 24h. The assembled VLP-
QDs were then filtered by using .5mL Amicon Ultra filter units (100kDa MWCO) and 
reconstituted in PBS to concentrate and to remove unassembled materials. The 
concentrated VLP-QDs were stored at 4 °C for downstream analysis.  
Quantification of ssDNA  
After removal of the supernatant containing the capsid subunits, the resulting DNA pellet 
was reconstituted in 30uL ultra-pure H2O and quantified using a Nanodrop 2000c. 
Transmission Electron Microscopy 
Electron micrographs were taken using a JEOL JEM 2100 transmission electron 
microscope operated at an accelerating voltage of 110kV, equipped with a CCD camera. 
5uL of VLP-QD sample was applied to a plasma cleaned carbon coated copper grid (cat 
cu-300HD, pacific grid tech) for 10 min. Excess sample was removed using filter paper 
followed by 4, 45sec wash steps with ultra-pure H2O. The grid was negatively stained with 
5uL of Uranyl Acetate Replacement Stain (cat. 22405, Electron Microscopy Sciences) for 
30 min using a 4x dilution followed by 4, 45sec wash steps with ultra-pure H2O. The grid 
was placed in a petri dish sealed with parafilm to dry overnight.  
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Dynamic Light Scattering 
Dynamic Light Scattering (DLS, Brookhaven Omni) was used to determine the reassembly 
of AAV VLPs in the absence of QDs. In preparation for DLS, samples were dialyzed 
against 10mM NaCl for 24h at 4 °C.   
Quantification of VLP-QD 
VLP-QDs were quantified using Spark Multimode Microplate reader. The fluorescence 
intensity of VLP-QDs was compared to a standard curve of known quantities of QDs to 
estimate the concentration of the VLP-QD sample. 
Cellular Uptake 
Uptake experiments were performed using human embryonic kidney (HEK) cells because 
it has been demonstrated they readily express heparin sulfate proteoglycan (HSPG) which 
acts as the main receptor to AAV2 88. HEK cells were seeded onto coverslips and left 
overnight to attach. QDs (2.4x1011 QD/mL) or VLP-QD (2x109 VLP/mL) were combined 
with fresh cell medium and incubated on HEK ceclls for 3 hours. Cells were then fixed in 
4% formaldehyde for 10 minutes followed by staining with Hoechst at a concentration of 
2µg/mL for 15 minutes followed by a PBS wash. Coverslips were then mounted on glass 
slides and imaged on a Zeiss 800 LSM microscope equipped with a 20x objective. Because 
Hoechst and QDs both excite in similar ranges, the QDs were imaged on a cy3 channel as 





Results and Discussion 
Virion Disassembly 
In order to verify the disassembly of AAV2, we quantified the ssDNA after dialysis against 
500 mM CaCl2. Two different amounts of AAV2, 5x1010 viral genomes (vg) and 1.5x1011 
vg were disassembled and centrifuged to isolate the ssDNA. The average amount of ssDNA 
obtained in the 5x1010 vg preparation was 49.57±28.2 ng and the average ssDNA obtained 
in the 1.5x1011 vg preparation was 143±9.9 ng, consistant with a 3x increase in number of 
AAV2 (Figure 2.1A). The estimated DNA amount for the 5x1010 vg and 1.5x1011 vg 
preparations were 32.75 ng and 98.25 ng, respectively. Given that the isolated DNA was 
quantified using a Nanodrop, the overestimation in concentration and large standard 
deviation is consistent with previously published data89. The total amount of measured 
ssDNA for each preparation was compared to a calculated estimate from the molecular 
weight and length of the AAV2-ITR’s combined with the Cytomegalovirus (CMV) 
promoter, multiplied by the number of particles. 
 
 
                                                                                     
 
Figure 2.1: Verification of the disassembly of AAV2. A) Quantification of DNA 





After verification of virion disassembly, reassembly conditions were then evaluated. 
Reassembly was first attempted without the presence of QDs to ensure formation of 
spherical VLPs before addressing QD encapsulation. Reassembly buffer was prepared 
using a range of KCl concentrations: 1 mM, 10 mM, 50 mM, and 100 mM. This range was 
chosen to attempt to mimic the intracellular concentrations of K+ and Cl-, ~140mM and 
~4mM, respectively90. Reassembly was measured after dialysis against reassembly buffer 
for 24 hours followed by dialysis against 10 mM NaCl to prepare the sample for DLS. Five 
DLS measurements were recorded for each condition, and the average of all measurements 
was plotted (Figure 2.2A). The mode diameters for the conditions were 26.25 nm, 44.89 





Figure 2.2: Analysis of reassembled VLPs. A) size distribution determined by 
DLS using reassembly buffers with varying ionic strengths B) TEM image of 
reassembled VLP in 1 mM KCl. Scale bar represents 25 nm. 
Although the mode diameters of the 50 nm and 100 nm KCl buffers appear very small, the 
mode diameters of each individual measurement were inconsistent, indicating the 




data, it was determined that reassembly buffer containing 1 mM KCl generated the most 
reproduceable VLPs that were closest in size to AAV2. At 1mM KCl, VLP assembly was 
likely due to electrostatic interactions, because as ionic strength is increased a ‘shielding 
effect’ is generated which allows protein-protein and Van der Waals forces to dominate. 
This is consistent with previous work using cowpea chlorotic mottle virus (CCMV), a 
28nm non-enveloped, icosahedral virus, which observed formation of smaller VLPs while 
using a lower ionic strength buffer; they determined that a decrease in ionic strength lead 
to the formation of smaller VLPs and was mainly driven by electrostatic interactions, 
whereas an increased ionic strength lead to formation of larger VLPs driven by protein-
protein interactions91. The reassembled VLPs were then imaged using transmission 
electron microscopy (TEM) to verify the DLS data (Figure 2.2B).  
Reassembly around Quantum Dots 
After the verification of the size and shape of the VLPs using DLS and TEM, reassembly 
of VLPs with QDs was performed using two different QDs, with an emission maximum of 
605 nm (QD605) and 525nm (QD525). When the QD605s were used, the VLP size closely 
resembled that of AAV2, however it was difficult to determine whether the QD605s were 
attached or partially encapsulated (Figure 2.3A). It was determined that increasing the 
image contrast could help solve this problem because traditionally it is difficult to image a 
biologic substance using TEM without the presence of a heavy-metal stain such as uranyl 
acetate. To achieve this, uranyl acetate replacement stain was added to the same grid 
imaged in Figure 2.3A and, as expected, the contrast of the image was improved (Figure 
2.3B). Even though it was easier to identify the outline of the individual VLPs, the QDs 
still appeared to be attached to the capsid rather than inside their core. Rather than 
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optimizing reassembly with the QD605s, QD525s were used instead, because QDs with 
smaller emitting wavelengths also have a smaller diameter92. After this small change, VLPs 
encapsulating single QD525s were observed (Figure 2.3C). The use of QD525s also 
significantly decreased the number of free QDs after purification using 100kDa MWCO 
spin filter, reinforcing the notion that QD525s had a smaller diameter than QD605s. A high 
magnification image was also taken to help identify the spherical VLP capsid around the 
dense, black QD525 (Figure 2.3D). Further optimization of stain time and concentration 









Figure 2.3: Optimizing VLP-QD formation. All TEM images of VLP-QDs were 
assembled using 1 mM KCl reassembly buffer and the following conditions: A) 
QD605. B) QD605s and uranyl acetate replacement stain C) QD525s and uranyl 








capsid protein shell and II points to the QD positioned at its core. Scale bar depicts 
20 nm.   
Before cellular uptake studies were conducted, a fluorescent microplate assay was 
performed to assess total fluorescence and provide an estimate of the number of VLP-
QD525s present in our sample. The concentration was determined to be 4.17x1010 VLP/mL 
(Figure 2.4). The standard curve generated used concentrations between 2.46x109 NP/mL 
and 9.6x1014 NP/mL. A hyperbolic curve was fit to the fluorescence intensity, as the 
concentration/fluorescence intensity is non-linear, however the actual relationship is 







Figure 2.4: Estimation of VLP-QD concentration. A hyperbolic curve was used 
to fit the QD concentrations using the following parameters: Bmax=95570, 
Kd=7.976x1014)  
Particles were added, QD525 (2.4x1011 QD/mL) or VLP-QD (2x109 VLP/mL), to 
determine cellular uptake in vitro. HEK cells were incubated with QDs or VLP-QDs for 3 
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hours, washed with PBS, fixed, then imaged. There was no observed fluorescence in the 
control image (Figure 2.5A). Comparable uptake of QDs (Figure 2.5B) and VLP-QDs 
(Figure 2.5C) can be seen inside small red vesicles. The QD and VLP-QD look very 
similar, however there were 100x higher concentration of QD than VLP-QD, indicating 
that VLP-QD may have utilized receptor-mediated endocytosis rather than passive uptake 






Figure 2.5: Uptake of VLP-QD. A) HEK cells stained with Hoechst. B) HEK cells 
stained with Hoechst and incubated with QD525 C) HEK cells stained with 
Hoechst and incubated with VLP-QD525. Scale bars represent 50µm. 
Future Directions 
The results of this study demonstrate that formation of VLPs from disassembled AAV2 
CPs is possible and that the incorporation of QD525 into the core of these particles can be 
achieved. The VLP-QD525 particles have the potential to improve the imaging 
methodologies currently used to assess biodistribution post-administration. However, 
before this is a real possibility, they must be further characterized to confirm they act 
sufficiently like AAV2.   
A B C 
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Future studies should focus on methods to identify whether the capsid formation of VLP-
QD525s is comparable to AAV2, such as an AAV2 titration ELISA, and to confirm which 
capsid proteins make up the VLP by using immunoprecipitation or fast protein liquid 
chromatography (FPLC). The AAV2 titration ELISA assay uses the A20 antibody, which 
only binds to a specific motif found on an intact AAV2 particle. Preliminary ELISAs were 
inconclusive due to the low absorbance values observed. For initial tests, a 1:5 dilution of 
the VLP-QD525 sample was used to conserve sample for additional experiments. Had a 
dilution not been used, the absorbance value may have been within the limit of detection 
and provided a better estimate of the number of VLP-QDs that had a similar protein 
structure to the AAV2 capsid. This assay could also be performed on disassembled AAV2 
to further confirm successful disassembly. 
Immunoprecipitation utilizes antibodies hybridized to a bead to separate a heterogeneous 
protein sample. In this case, a series of immunoprecipitations could be performed using 
antibodies that target each AAV2 capsid protein to systematically determine which proteins 
coexist with QD fluorescence after unassembled materials have been removed. Similar 
experiments could be performed using FPLC; a commercially available heparin column 
could be used to determine if VLP-QD525s interact with the same primary receptor as 
AAV2. 
In summary, we have demonstrated that by performing dialysis against simple buffers, 
AAV2 can be disassembled into protein subunits, reassembled into a VLP, and a QD525 
can be inserted into its core. Our results provide evidence that the VLP-QD525s can be up-
taken by HEK cells in vitro, however further studies are required to determine its primary 
receptor for cell entry and whether the capsid structure is comparable to AAV2.  
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Chapter Three: Diffusion of Extracellular Vesicles through Human 
Mucus 
Introduction 
Recent studies have indicated that extracellular vesicles (EVs) exhibit therapeutic 
properties and have become appealing in gene therapy and regenerative medicine95. The 
vast majority of these studies rely on the EV cargo from mesenchymal stem cells rather 
than the loading of a therapeutic. EVs play an important role in intercellular 
communication in the lungs, which is a good indicator they can move through the complex 
mucus barrier with ease, however no published studies to date have been done to elucidate 
this ability. Because of the diversity of cargo that can be loaded into EVs and the fact they 
are inherently part of the pulmonary immune system, we were interested in exploring their 
mucus penetrating ability.   
Pulmonary diseases such as cystic fibrosis (CF), asthma and chronic obstructive pulmonary 
disease (COPD) are particularly difficult to treat because of the thick mucus barrier they 
cause. The standard treatment options are typically inhaled therapies, which have many 
factors that can be tailored to alter a drug’s efficacy, such as size and shape65. For an inhaled 
therapeutic to be effective in the clinic, it must be able to penetrate through mucus. Various 
inhaled therapies for lung disease have been tested, such as nanoparticles and dendrimers, 
however, none of these drugs have made it to the clinic96. Many of these drugs are made 
of non-biological materials, whereas EVs are endogenously expressed. Another issue with 
using exogenous materials is the difficulty of selectively targeting diseased cells opposed 
to healthy ones. This challenge can potentially be overcome by generating EVs from a cell 
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line with the same disease97. Zhang et al. showed that EVs can deliver siRNA and miRNA 
into mouse lungs in vivo, however experiments were performed on healthy mice, rather 
than a diseased model98. Their targeting potential as well as their loading potential give 
them promise as a drug delivery system.  
CF is caused by one or many mutations to the cystic fibrosis transmembrane regulator 
(CFTR), a membrane protein that functions as a Cl- channel. These mutations result in the 
degradation of the CFTR during transport to the membrane or make it dysfunctional. When 
CFTR is not actively transporting Cl-, mucociliary clearance is significantly decreased and 
the mucus buildup is immense. The most common CF mutation is a deletion in 
phenylalanine 508 (F508del) that causes a trafficking defect in the ion channel. It has been 
shown in vitro that miRNA-16 has the potential to correct this defect and return the CFTR 
to a semi-functional state99. Although miRNA-16 was not delivered via an EV, miRNA 
can easily be loaded into one by using one of the aforementioned techniques. 
Using multiple particle tracking analysis, we investigated the ability for EV derived from 
human embryonic kidney cells (HEK) or cystic fibrosis bronchial epithelial cells (CFBE) 
to penetrate mucus taken from healthy patients without lung disease. We hypothesized that 
EVs derived from CFBE cells would have higher diffusivity in human mucus when 
compared to EVs derived from HEK cells because even though they originate from a 
diseased cell line, they originate in the lung and will still portray membrane proteins that 
allow for efficient movement through mucus. This study aims to be a first step to 
determining the mucus penetrating properties of two different types of EVs to evaluate 




Materials and Methods 
Cell Culture 
All cells were grown in Dulbecco’s Modified Eagle’s Medium with 10% Fetal Bovine 
Serum and penicillin/streptomycin.  
EV Purification 
Cells were grown in T125 flasks. Conditioned media was collected every 24h until 
confluency was reached. The collected media was stored at 4˚C until 500mL of conditioned 
media was collected in total. Once 500mL was collected, it was centrifuged at 1,000 x g 
for 10 minutes to remove detached cells. For all spins, 1-2mL was left in the tube as not to 
disturb the pellet. The supernatant was transferred to a new tube and was centrifuged again 
at 2,000 x g for 20min at 4˚C to remove cellular debris and apoptotic bodies. The 
supernatant was again transferred to a new tube and centrifuged at 10,000 x g for 30min at 
4˚C to remove large vesicles. Lastly, the supernatant was transferred to an ultracentrifuge 
tube and centrifuged at 100,000 x g for 2hr at 4˚C. The supernatant was then removed, and 
the pellet was carefully reconstituted in 500µL of PBS. The newly resuspended EVs were 
then placed into a 300kDa ultrafiltration tube and centrifuged at 8,000 x g for 1min at 4˚C. 
They were then washed with 500µL PBS. After 3 washes total, the purified EVs were 
resuspended in 500µL PBS. The size and concentration were verified using a Nanosite 
LM10 using NTA analytical software version 2.4 and BCA assay, respectively.  
Loading fluorescently labeled miRNA into purified EVs 
Loading miRNA was performed via pH gradient. The EVs (300µg/ml) were first combined 
with 70% Ethanol and allowed to dehydrate for 12hr in a biological safety cabinet. Next 
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the dehydrated EVs were rehydrated in citrate buffer, pH 2.5, and placed on a shaker for 1 
hr at 25˚C. After 30 min the EVs were resuspended and placed back on the shaker. The 
EVs were pipetted into dialysis tubing and dialyzed against 1X HBS buffer. The buffer was 
exchanged every 2 hours, three times, then left overnight. EVs were collected the following 
morning and were purified using a 100kDa spin filter. They were centrifuge at 3,000 x g 
for 30min at 4˚C. The sample was resuspended in 300µL of 1X HBS and filtered through 
a .22µm filter. BCA and NTA analysis were performed to obtain the EV to protein ratio to 
determine purity. 100µg of EVs were then combined with 1nmol of miRNA and were 
incubated for 2 hr at 25˚C. The sample was then washed three times using 500µL of PBS 
using a 300kDa MWCO Nanosep tube (8,000 x g for 15min). EVs were resuspended in 
100uL PBS.  
Sample preparation for fluorescent video microscopy 
Slides were prepared by sealing a rubber O-ring on glass slides with vacuum grease. 
Nanoparticles were sonicated for 30 minutes prior to use. Human mucus was thawed on 
ice, then 20µL was transferred within the newly formed O-ring well. The sample was 
incubated at room temperature for 10 minutes to ensure it was no longer chilled. Peg-coated 
nanoparticles, 0.5µL of ~.002% w/v, were added and mixed into a seperate human mucus 
sample as a control. EVs used in tracking experiments were concentrated using a 100kDa 
spin filter and reconstituted in 20µL PBS. 1µL of the concentrated sample was added to 
20uL of human mucus which was then stirred. Measurements were collected using a Zeiss 
800 LSM microscope equipped with a x63/1.20 W Korr UV VIS IR water-immersion 
objective and an Axiocam 702 camera with resolution of .093µm/pixel. Images were 
collected at a frame rate of 33.33 Hz for 10 seconds.  
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Particle Tracking Data Analysis  
The particle tracking data analysis is based on previously developed image processing 
algorithm100. An intensity threshold was first set to distinguish the particles from the 
background, then the eccentricity threshold was set to ensure only spherical particles were 
selected to distinguish from aggregates or oddly-shaped particles. The centers of the 
nanoparticles above the brightness threshold and below the eccentricity cutoff are assigned 
a center based on their (x,y) image location. The centers were then tracked frame by frame 
allowing for the calculation of their mean-squared displacement (MSD). The average MSD 
value at 1 second was used to compare diffusion rates between samples.  
Results and Discussion 
Extracellular Vesicle Characterization 
The size distribution and concentration of the extracellular vesicles (EV) was determined 
using nanoparticle tracking analysis (NTA) before and after pH loading (Figure 3.1A and 
B). The mode diameter was used to best represent the size-population with the highest 
concentration. The mode diameter for EV derived from HEK cells (HEK-EV) was 
139.5±41.3nm compared to 139.5±54.9nm after pH loading (Figure 3.1C). The same 
analysis was also performed on EV derived from CFBE cells (CFBE-EV), whose mode 
diameter was 165.1±63.8nm before loading and 168.4±100.7nm after loading indicating 














Figure 3.1: EV size distribution determined by NTA. A) Size distribution of 
HEK-EV before and after loading. B) Size distribution of CFBE-EV before and 
after loading. C) Mode diamter of HEK-EV. D) Mode diameter of CFBE-EV. All 
EV characterization experiments were performed by Stephanie Kronstadt in the Jay 
Lab at University of Maryland. 
In the characterization of the concentration and size of the EV it was expected that the 
concentration would decrease slightly and that the size distribution would remain pretty 
much constant as we saw with the HEK-EV. The CFBE-EV size distribution shifted larger 
after loading while the mode diameter remained unchanged. This indicated that there may 
have been other proteins present in the preparation that led to particle aggregation or that 





that the CFBE-EV come from a diseased cell line with cystic fibrosis (CF), and it has been 
shown that CF cells produce many more vesicles than other cell lines. This could indicate 
that means that more strenuous purification measures are required for this particular cell-
line that are unnecessary for EV from other cell lines101.  
Diffusion in Human Mucus 
After NTA characterization, the mobility of HEK-EV and CFBE-EV in human mucus was 
evaluated using fluorescent video microscopy to measure the MSD of EVs loaded with 
fluorescently labeled miRNA. The diffusivity of the HEK-EVs was significantly lower 
than the control particles in each sample (Figure 3.2A). In each sample tested with CFBE-
EV, there was also significant decrease in diffusivity when compared to the 100nm PEG-
coated nanoparticles (Figure 3.2B). When the combined logMSD values were compared 
for all samples, the HEK-EV and CFBE-EV both were significantly less mobile than the 
control. However, when the HEK-EV and CFBE-EV were directly compared the CFBE-
EV had a significantly higher logMSD (Figure 3.2C). 
The HEK-EV and the CFBE-EV had significantly lower MSD values in each of the mucus 
samples, however when directly compared, the CFBE-EV were significantly more mobile 
than the HEK-EV. This indicated that CFBE-EV can diffuse much better, perhaps, because 
they are derived from lung cells whereas HEK-EVs are derived from kidney cells. 
Although CFBE-EVs had a higher combined logMSD than the HEK-EVs, the HEK-EV 
experiments were performed in human mucus with one less freeze-thaw which has been 
shown to impact the MSD of nanoparticles100.  
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Although both HEK-EVs and CFBE-EV had significantly lower MSD than the 100nm-
PEG coated particles, it shows that it is possible to improve the mobility of EV in human 
mucus simply by using a different cell line for EV generation, indicating that the utilization 
of other lung EVs as drug delivery vehicles is possible. Improvement of EV diffusion 
through mucus is the next barrier to overcome as the transfer of the CFTR gene in vitro has 
already been demonstrated using EVs derived from Calu-3 and A549101. With the 
improvement of EV loading techniques, miRNA16 could potentially be loaded into EVs 
as it has been shown to exhibit CFTR restorative properties97.  








Figure 3.2: Diffusion of EV in Human Mucus. A) MSD of HEK-EV in human 
mucus. B) MSD of CFBE-EV in human mucus. Significance was determined using 
the Mann-Whitney test (*P< 0.0001). C) Combined MSD of HEK-EV and CFBE-





comparison test were performed to determine significance between the combnined 
datasets (*P< 0.0001). 
Future Directions 
EVs have untapped potential to be effective delivery vectors. Not only are there many other 
sources of EVs that can be investigated, modifications to their lipid membrane could also 
be done to improve their ability to move unhindered through the mucus barrier in the lung.  
Future experiments should focus on the utilization of air-liquid-interface (ALI) cultures to 
identify EV populations that can penetrate through the mucus barrier. ALI cultures would 
provide useful information on protein expression as well as mucus penetration, as similar 
experiments have been performed using other gene delivery vectors102. ALI cultures 
expressing a diseased phenotype could also be used to identify EVs suited to treat specific 
mutations. The utilization of QDs into the core of EVs could also be investigated to 
improve the quality of bioimaging, as this has only recently begun to be explored102.  
This work helped to provide a very basic understanding of EV mobility in human mucus 
that will hopefully encourage others to investigate different types of EVs further and to 








Chapter 4: Summery and Conclusions 
 
Viral-Like-Particle Quantum Dot Encapsulation 
The aim of this work was to improve the labeling methodology of AAV to gain the ability 
to assess biodistribution directly post-administration in vivo. Using current methods, a 
reporter gene must be expressed before any type of signal can be obtained. This process 
can take days to weeks, leaving a large window of opportunity for a QD based approach. 
Here, we engineered VLPs using capsid proteins from AAV2 and encapsulated a QD into 
their core to combine the immense brightness and photostability of QDs to the broad utility 
of the AAV vector for gene delivery. By adapting a method that has been demonstrated in 
other non-enveloped, icosahedral viruses, we showed that it is possible to disassemble 
intact AAV2 virions and that they can be reassembled using dialysis. This is the first study 
to date that uses dialysis to demonstrate the disassembly and reassembly of VLPs using 
AAV capsid proteins.  
Extracellular Vesicle Diffusion through human mucus 
We were interested in investigating EVs mucus penetrating ability. EVs are an 
endogenously expressed gene delivery vector with largely untapped potential. EVs have 
been observed to deliver genes in vitro however no studies to date have been done to 
demonstrate their ability to navigate through the human mucus barrier; one that first must 
be crossed for efficient drug delivery. Here we demonstrated that CFBE-EV could diffuse 
through human mucus significantly faster than HEK-EV even though the mode diameter 
of the EV population was slightly larger. These results give good indication that EVs 
obtained from cells derived from lung epithelia have the ability to penetrate human mucus 
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significantly better than EV obtained from cells of other origins however further 
experiments are necessary to fully elucidate their gene delivery capabilities through a 
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